BACIL PHARMA LTD.

Bacil Pharma Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved these results in a meeting held on August 12, 2026. The company will submit the results to the exchange and make them available on its website. The results will also be published in newspapers in due course. The limited review of the financial results was carried out by the statutory auditors.

Bacil Pharma Ltd announced that its Board of Directors, in a meeting held on August 12, 2026, approved the unaudited financial results for the quarter ended June 30, 2026. The company will submit these results to the exchange and make them available on its website. The board also reviewed other business activities. The meeting commenced at 3:00 PM and concluded at 4:00 PM. The results are scheduled for publication in newspapers in due course.

Bacil Pharma Ltd has announced the incorporation of its wholly owned subsidiary, Bacil Research & Development Private Limited. The new entity was officially incorporated on July 28, 2026, under the Companies Act, 2013. This move signifies the company's strategic expansion into research and development activities, aiming to foster innovation and potentially develop new pharmaceutical products or technologies. The subsidiary's incorporation is a key step in Bacil Pharma's growth strategy.

Bacil Pharma Ltd announced a board meeting where it approved a Rights Issue of equity shares to raise up to ₹50 crore. The company also approved an increase in its authorized share capital to ₹65 crore. Intermediaries for the Rights Issue, including a registrar, banker, and monitoring agency, were appointed. Additionally, the board accepted the resignations of two Independent Directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya, citing pre-occupation with other assignments. A Rights Issue Committee was formed, and Ms. Chaitali Kalpataru Shah, Executive Director & CFO, was authorized to handle related documentation. The trading window remains closed until 48 hours after the board meeting outcome.

Bacil Pharma Ltd's Board of Directors has approved a Rights Issue to raise up to ₹50 crore. The company also approved an increase in its authorized share capital to ₹65 crore. In addition, the board accepted the resignations of two Independent Directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya, citing pre-occupation with other assignments. Intermediaries for the Rights Issue, including a registrar, banker, and monitoring agency, have been appointed. A Rights Issue Committee has been formed, and Ms. Chaitali Kalpataru Shah (Executive Director & CFO) and the Company Secretary have been authorized to handle the issue's documentation.

Bacil Pharma Ltd's Board of Directors has approved a proposal to raise funds up to ₹50 crore through a Rights Issue of equity shares. The board also approved an increase in the company's authorized share capital by ₹45 crore to ₹65 crore, subject to shareholder approval. Intermediaries for the Rights Issue, including a registrar, banker, and monitoring agency, have been appointed. Additionally, the board accepted the resignation of two independent directors and formed a Rights Issue Committee. The trading window will remain closed until 48 hours after the board meeting outcome is declared.

Bacil Pharma Ltd's Board of Directors met on July 9, 2026, approving a Rights Issue of equity shares to raise up to ₹50 crore. The board also approved an increase in authorized share capital by ₹45 crore to ₹65 crore, subject to shareholder approval. Intermediaries for the Rights Issue were appointed, including Purva Sharegistry as Registrar and Axis Bank as Banker. The board accepted the resignations of two Independent Directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya. A Rights Issue Committee was formed, and Ms. Chaitali Kalpataru Shah (Executive Director & CFO) and the Company Secretary were authorized to execute necessary documents for the Rights Issue. The trading window remains closed until 48 hours after the meeting outcome.

Bacil Pharma Ltd's Board of Directors has approved a proposal to raise up to ₹50 crore through a Rights Issue of equity shares. The board also approved an increase in the authorized share capital by ₹45 crore to ₹65 crore, subject to shareholder approval. Intermediaries for the Rights Issue, including Purva Sharegistry (India) Private Limited as Registrar and Axis Bank as Banker, were appointed. The board accepted the resignations of Independent Directors Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya. A Rights Issue Committee was formed, and Ms. Chaitali Kalpataru Shah and the Company Secretary were authorized to execute necessary documents for the Rights Issue. The trading window remains closed until 48 hours after the board meeting outcome.

Bacil Pharma Ltd has received approval from the Registrar of Companies, Central Registration Centre (CRC), Ministry of Corporate Affairs, for the name 'Bacil Research & Development Private Limited' for its proposed wholly-owned subsidiary. The name reservation is valid until July 26, 2026. The incorporation process is underway, and further disclosures will be made upon completion and receipt of the Certificate of Incorporation. This intimation is made pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Bacil Pharma Ltd has announced a board meeting scheduled for July 9, 2026, to consider a proposal for raising funds up to ₹50 crore through a Rights Issue of equity shares. The company also plans to discuss increasing its authorized share capital, altering the Memorandum of Association, and approving the terms of the Rights Issue. Additionally, the board will discuss director appointments and resignations. The trading window will remain closed for designated persons until 48 hours after the meeting's outcome is declared.